Press Releases

Press Releases

Lexington--(BUSINESS WIRE)– May 28, 2014 Quanterix, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, announced today it has been selected as a Red Herring Top 100 North America award winner. The Top 100 award winners are…
LEXINGTON, MA – March 5, 2015 Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), will use Quanterix…
LEXINGTON, MA – July 23, 2015 Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced it was named a final winner of GE and the NFL’s Head Health Challenge I’s phase two grant. There were…
December 2, 2015
Quanterix announces the success of the company’s recent user conference entitled, “Proteins Powering NextGen Healthcare: San Francisco.”
March 8, 2016
Quanterix announces that Kevin Hrusovsky, Executive Chairman and CEO, will present at the Cowen and Company 36th Annual Health Care Conference.
October 18, 2016
Quanterix announces that it has been named the “Late Stage Leader” Buzz of BIO winner. As a winner of this award – which recognizes innovative companies that have raised more than $25 million as of July 1, 2016 – Quanterix will also be presenting at the 2016 BIO Investor Forum.
May 1, 2017
Kevin Hrusovsky, CEO and Executive Chairman at Quanterix, will join a distinguished panel of industry experts to discuss the state and future of precision cardiovascular medicine at the World Medical Innovation Forum. The panel is taking place Tuesday, May 2nd, from 2:00-2:50pm.
CAMBRIDGE, MA – September 2, 2009 – Quanterix Corporation, the leader in single molecule detection, announced today that David Okrongly, Ph.D. has been appointed Chief Executive Officer and a member of the company’s Board of Directors. Dr. Okrongly replaces co-founder and interim CEO, Nicholas…
CAMBRIDGE, MA – April 12, 2011 – Quanterix Corporation, enabling a new generation of diagnostics based on revolutionary Single Molecule Array (SiMoA™) technology, today announced that significant elevations in blood levels of amyloid beta (Aβ) 42 peptide, a component of the plaques that are a…